These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 22099989)

  • 41. The mutational spectrum of HRAS, KRAS, NRAS and FGFR3 genes in bladder cancer.
    Ouerhani S; Elgaaied AB
    Cancer Biomark; 2011-2012; 10(6):259-66. PubMed ID: 22820081
    [TBL] [Abstract][Full Text] [Related]  

  • 42. p53 and microvessel density in primary resection specimens of superficial bladder cancer.
    Reiher F; Ozer O; Pins M; Jovanovic BD; Eggener S; Campbell SC
    J Urol; 2002 Mar; 167(3):1469-74. PubMed ID: 11832772
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oncogenic role of fibroblast growth factor receptor 3 in tumorigenesis of urinary bladder cancer.
    Pandith AA; Shah ZA; Siddiqi MA
    Urol Oncol; 2013 May; 31(4):398-406. PubMed ID: 20822928
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nonprimary pT1 nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin is associated with higher risk of progression compared to primary T1 tumors.
    Alkhateeb SS; Van Rhijn BW; Finelli A; van der Kwast T; Evans A; Hanna S; Vajpeyi R; Fleshner NE; Jewett MA; Zlotta AR
    J Urol; 2010 Jul; 184(1):81-6. PubMed ID: 20478593
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combining molecular and pathologic data to prognosticate non-muscle-invasive bladder cancer.
    van Rhijn BW
    Urol Oncol; 2012; 30(4):518-23. PubMed ID: 22742564
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Optimization of nonmuscle invasive bladder cancer recurrence detection using a urine based FGFR3 mutation assay.
    Zuiverloon TC; Tjin SS; Busstra M; Bangma CH; Boevé ER; Zwarthoff EC
    J Urol; 2011 Aug; 186(2):707-12. PubMed ID: 21683397
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of 2004 and 1973 World Health Organization grading systems and their relationship to pathologic staging for predicting long-term prognosis in patients with urothelial carcinoma.
    Cao D; Vollmer RT; Luly J; Jain S; Roytman TM; Ferris CW; Hudson MA
    Urology; 2010 Sep; 76(3):593-9. PubMed ID: 20381131
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Selective detection of inactivating mutations of the tumor suppressor gene p53 in bladder tumors.
    Pfister C; Flaman JM; Martin C; Grise P; Frebourg T
    J Urol; 1999 Jun; 161(6):1973-5. PubMed ID: 10332483
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Frequent association of p53 gene mutation in invasive bladder cancer.
    Fujimoto K; Yamada Y; Okajima E; Kakizoe T; Sasaki H; Sugimura T; Terada M
    Cancer Res; 1992 Mar; 52(6):1393-8. PubMed ID: 1540947
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders.
    van Rhijn BW; van Tilborg AA; Lurkin I; Bonaventure J; de Vries A; Thiery JP; van der Kwast TH; Zwarthoff EC; Radvanyi F
    Eur J Hum Genet; 2002 Dec; 10(12):819-24. PubMed ID: 12461689
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High CDKN2A/p16 and Low FGFR3 Expression Predict Progressive Potential of Stage pT1 Urothelial Bladder Carcinoma.
    Breyer J; Wirtz RM; Erben P; Worst TS; Stoehr R; Eckstein M; Bertz S; Sikic D; Denzinger S; Burger M; Hartmann A; Otto W;
    Clin Genitourin Cancer; 2018 Aug; 16(4):248-256.e2. PubMed ID: 29525349
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Frequent FGFR3 mutations in urothelial papilloma.
    van Rhijn BW; Montironi R; Zwarthoff EC; Jöbsis AC; van der Kwast TH
    J Pathol; 2002 Oct; 198(2):245-51. PubMed ID: 12237885
    [TBL] [Abstract][Full Text] [Related]  

  • 53. p53 predictive value for pT1-2 N0 disease at radical cystectomy.
    Shariat SF; Lotan Y; Karakiewicz PI; Ashfaq R; Isbarn H; Fradet Y; Bastian PJ; Nielsen ME; Capitanio U; Jeldres C; Montorsi F; Müller SC; Karam JA; Heukamp LC; Netto G; Lerner SP; Sagalowsky AI; Cote RJ
    J Urol; 2009 Sep; 182(3):907-13. PubMed ID: 19616250
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A 3-plex methylation assay combined with the FGFR3 mutation assay sensitively detects recurrent bladder cancer in voided urine.
    Kandimalla R; Masius R; Beukers W; Bangma CH; Orntoft TF; Dyrskjot L; van Leeuwen N; Lingsma H; van Tilborg AA; Zwarthoff EC
    Clin Cancer Res; 2013 Sep; 19(17):4760-9. PubMed ID: 23842048
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Some molecular-genetic markers, defining the pathogenesis of superficial and invasive bladder cancer].
    Babaian AIu; Kariakin OB; Teplov AA; Zaletaev DV; Nemtsova MV
    Mol Biol (Mosk); 2011; 45(6):1012-6. PubMed ID: 22295571
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Absence of FGFR3 mutations in urinary bladder tumours of rats and mice treated with N-butyl-N-(-4-hydroxybutyl)nitrosamine.
    Dunois-Lardé C; Levrel O; Brams A; Thiery JP; Radvanyi F
    Mol Carcinog; 2005 Mar; 42(3):142-9. PubMed ID: 15690367
    [TBL] [Abstract][Full Text] [Related]  

  • 57. p53 mutations in bladder tumors inactivate the transactivation of the p21 and Bax genes, and have a predictive value for the clinical outcome after bacillus Calmette-Guerin therapy.
    Pfister C; Flaman JM; Dunet F; Grise P; Frebourg T
    J Urol; 1999 Jul; 162(1):69-73. PubMed ID: 10379742
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Motility-related protein 1 (MRP-1/CD9) expression in urothelial bladder carcinoma and its relation to tumor recurrence and progression.
    Mhawech P; Herrmann F; Coassin M; Guillou L; Iselin CE
    Cancer; 2003 Oct; 98(8):1649-57. PubMed ID: 14534881
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fluorescence in situ hybridization identifies more aggressive types of primarily noninvasive (stage pTa) bladder cancer.
    Pycha A; Mian C; Haitel A; Hofbauer J; Wiener H; Marberger M
    J Urol; 1997 Jun; 157(6):2116-9. PubMed ID: 9146595
    [TBL] [Abstract][Full Text] [Related]  

  • 60. p53 mutations and prognosis in bladder tumors.
    Uchida T; Wada C; Ishida H; Wang C; Egawa S; Yokoyama E; Kameya T; Koshiba K
    J Urol; 1995 Apr; 153(4):1097-104. PubMed ID: 7869472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.